Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.

What Was Tested

This randomized controlled trial looks at Glucagon in the context of low blood pressure and orthostatic hypotension.

To assess the effect of LY2409021 on systolic blood pressure (SBP) in patients with type 2 diabetes.

Who Took Part

The study group was 270 subjects.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The subjects were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

In the crossover set-up each of the subjects took both Glucagon and the comparison in turn, acting as their own control.

Other measures included changes in glycemic control, serum lipids, and hepatic safety markers.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Biphenyl Compounds, Blood Pressure, Blood Pressure Monitoring, Ambulatory, Diabetes Mellitus, Type 2, Diabetic Angiopathies and Glycated Hemoglobin.

The authors tagged it with the keywords clinical trial, glucagon receptor antagonist and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 270 subjects in people with low blood pressure and orthostatic hypotension.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page, Low blood pressure and orthostatic hypotension research.